<DOC>
	<DOCNO>NCT00547469</DOCNO>
	<brief_summary>This study evaluate safety effectiveness investigational drug DDP733 treat female patient IBS-c. A placebo control utilized .</brief_summary>
	<brief_title>A Study Safety Effectiveness DDP733 Treating IBS With Constipation Females</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Female 18 65 year age , inclusive Patient experience recurrent abdominal pain discomfort least 3 day per month last 3 month symptom onset least 6 month prior diagnosis . The patient 's symptom must associate 1 follow : Improvement defecation Onset associate change frequency stool Onset associate change form ( appearance ) stool Negative serum urine pregnancy test Completion least six day daily diary assessment use phonein information system prior randomization Serious underlying disease , include psychiatric disorder Current history condition affect bowel transit Recent history biochemical structural abnormality gastrointestinal tract , gastrointestinal surgery , gastrointestinal infection Clinically significant abnormal examination finding laboratory test Inability stop take certain medication , plan change medication ( include herbal remedy ) could interfere study assessment Use drug ethanol may interfere compliance study procedure influence study outcome Presence medical condition could interfere interpretation study data Significant use nicotine caffeine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS-c</keyword>
	<keyword>IBS constipation</keyword>
	<keyword>woman IBS</keyword>
	<keyword>woman constipation</keyword>
</DOC>